These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 26472945)

  • 1. Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate.
    Phillips JT; Selmaj K; Gold R; Fox RJ; Havrdova E; Giovannoni G; Abourjaily H; Pace A; Novas M; Hotermans C; Viglietta V; Meltzer L
    Int J MS Care; 2015; 17(5):236-43. PubMed ID: 26472945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate.
    O'Gorman J; Russell HK; Li J; Phillips G; Kurukulasuriya NC; Viglietta V
    Clin Ther; 2015 Jul; 37(7):1402-1419.e5. PubMed ID: 25999183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
    Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
    Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Bismuth Subsalicylate on Gastrointestinal Tolerability in Healthy Volunteers Receiving Oral Delayed-release Dimethyl Fumarate: PREVENT, a Randomized, Multicenter, Double-blind, Placebo-controlled Study.
    Koulinska I; Riester K; Chalkias S; Edwards MR
    Clin Ther; 2018 Dec; 40(12):2021-2030.e1. PubMed ID: 30447891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal Tolerability of Delayed-Release Dimethyl Fumarate in a Multicenter, Open-Label Study of Patients with Relapsing Forms of Multiple Sclerosis (MANAGE).
    Fox EJ; Vasquez A; Grainger W; Ma TS; von Hehn C; Walsh J; Li J; Zambrano J
    Int J MS Care; 2016; 18(1):9-18. PubMed ID: 26917993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and CONFIRM.
    Fox RJ; Gold R; Phillips JT; Okwuokenye M; Zhang A; Marantz JL
    Neurol Ther; 2017 Dec; 6(2):175-187. PubMed ID: 28770420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panel.
    Phillips JT; Hutchinson M; Fox R; Gold R; Havrdova E
    Mult Scler Relat Disord; 2014 Jul; 3(4):513-9. PubMed ID: 25877064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies.
    Kita M; Fox RJ; Gold R; Giovannoni G; Phillips JT; Sarda SP; Kong J; Viglietta V; Sheikh SI; Okwuokenye M; Kappos L
    Clin Ther; 2014 Dec; 36(12):1958-1971. PubMed ID: 25315404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dimethyl Fumarate: A Review of Efficacy and Practical Management Strategies for Common Adverse Events in Patients with Multiple Sclerosis.
    Phillips JT; Agrella S; Fox RJ
    Int J MS Care; 2017; 19(2):74-83. PubMed ID: 32607065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers.
    Sheikh SI; Nestorov I; Russell H; O'Gorman J; Huang R; Milne GL; Scannevin RH; Novas M; Dawson KT
    Clin Ther; 2013 Oct; 35(10):1582-1594.e9. PubMed ID: 24139424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension.
    Ochi H; Niino M; Onizuka Y; Hiramatsu K; Hase M; Yun J; Matta A; Torii S
    Adv Ther; 2018 Oct; 35(10):1598-1611. PubMed ID: 30206820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and mitigation of gastrointestinal events in patients with relapsing-remitting multiple sclerosis receiving delayed-release dimethyl fumarate: a German phase IV study (TOLERATE).
    Gold R; Schlegel E; Elias-Hamp B; Albert C; Schmidt S; Tackenberg B; Xiao J; Schaak T; Salmen HC
    Ther Adv Neurol Disord; 2018; 11():1756286418768775. PubMed ID: 29707040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations.
    Prosperini L; Pontecorvo S
    Ther Clin Risk Manag; 2016; 12():339-50. PubMed ID: 27042079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study.
    Palte MJ; Wehr A; Tawa M; Perkin K; Leigh-Pemberton R; Hanna J; Miller C; Penner N
    Adv Ther; 2019 Nov; 36(11):3154-3165. PubMed ID: 31538304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study.
    Wundes A; Wray S; Gold R; Singer BA; Jasinska E; Ziemssen T; de Seze J; Repovic P; Chen H; Hanna J; Messer J; Miller C; Naismith RT
    Ther Adv Neurol Disord; 2021; 14():1756286421993999. PubMed ID: 33796143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Dimethyl Fumarate in Young Adults with Relapsing-Remitting Multiple Sclerosis: Analysis of the DEFINE, CONFIRM, and ENDORSE Studies.
    Amezcua L; Mao-Draayer Y; Vargas WS; Farber R; Schaefer S; Branco F; England SM; Belviso N; Lewin JB; Mendoza JP; Shankar SL;
    Neurol Ther; 2023 Jun; 12(3):883-897. PubMed ID: 37061656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis.
    Kappos L; Giovannoni G; Gold R; Phillips JT; Arnold DL; Hotermans C; Zhang A; Viglietta V; Fox RJ;
    Eur J Neurol; 2015 Apr; 22(4):664-71. PubMed ID: 25557371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies.
    Giovannoni G; Gold R; Fox RJ; Kappos L; Kita M; Yang M; Sarda SP; Zhang R; Viglietta V; Havrdova E
    Clin Ther; 2015 Nov; 37(11):2543-51. PubMed ID: 26526385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.
    Havrdova E; Giovannoni G; Gold R; Fox RJ; Kappos L; Phillips JT; Okwuokenye M; Marantz JL
    Eur J Neurol; 2017 May; 24(5):726-733. PubMed ID: 28328179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.